Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Adicet Bio Inc (ACET)

Adicet Bio Inc (ACET)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Adicet Bio, Inc. (ACET) Reports Q1 Loss, Misses Revenue Estimates Zacks - Tue May 9, 2023

Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of 2.70% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ACET : 2.20 (+1.85%)
URGN : 15.10 (unch)
Arcturus Therapeutics (ARCT) Q1 Earnings and Revenues Miss Estimates Zacks - Tue May 9, 2023

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -69.86% and 39.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ARCT : 29.31 (-3.68%)
ACET : 2.20 (+1.85%)
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Business Wire - Fri Apr 28, 2023

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on April...

ACET : 2.20 (+1.85%)
Legend Biotech Corporation Sponsored ADR (LEGN) Soars 19.6%: Is Further Upside Left in the Stock? Zacks - Thu Apr 20, 2023

Legend Biotech Corporation Sponsored ADR (LEGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that...

LEGN : 51.71 (-2.29%)
ACET : 2.20 (+1.85%)
Adicet Bio to Participate in 2023 Canaccord Genuity Horizons in Oncology Virtual Conference Business Wire - Thu Apr 13, 2023

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief...

ACET : 2.20 (+1.85%)
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Business Wire - Fri Mar 31, 2023

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on March...

ACET : 2.20 (+1.85%)
Adicet Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress Business Wire - Wed Mar 15, 2023

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights...

ACET : 2.20 (+1.85%)
Adicet Bio to Participate in 2023 Jefferies Biotech on the Bay Summit Business Wire - Thu Mar 9, 2023

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief...

ACET : 2.20 (+1.85%)
Akoya Biosciences (AKYA) Reports Q4 Loss, Tops Revenue Estimates Zacks - Mon Mar 6, 2023

Akoya (AKYA) delivered earnings and revenue surprises of -21.95% and 1.79%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

AKYA : 4.01 (-2.91%)
ACET : 2.20 (+1.85%)
Myriad Genetics (MYGN) Reports Q4 Loss, Tops Revenue Estimates Zacks - Tue Feb 28, 2023

Myriad (MYGN) delivered earnings and revenue surprises of 25% and 5.11%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

MYGN : 19.17 (-1.94%)
ACET : 2.20 (+1.85%)

Barchart Exclusives

Earnings Season Tactics: Strategies for Finding Profitable Options Trades Barchart - 9 minutes ago
Earnings season is here and we’ve already seen some big name companies report earnings including Citigroup, JP Morgan Chase, Delta Airlines, Wells Fargo and Blackrock. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot